Peking University Third Hospital
Beijing, Beijing Municipality, 100191, China
NCT Number: NCT06727955
To develop an artificial intelligence (AI) model to predict DR progression based on a prospective cohort database.With use of an innovative AI model and a validated machine learning algorithm, based on multimodal vascular and neuro imaging of the eye, the progression of diabetic microangiopathy especially the DR could successfully be predictse and fundamentally facilitate diabetes management.
Trial opening soon.
Get Notified40 year–80 year
All sexes
Observational
Beijing, Beijing Municipality, 100191, China
To develop an artificial intelligence (AI) model to predict DR progression based on a prospective cohort database.This study will first conduct a prospective single-center cohort, which will enroll 250 type 2 diabetes mellitus patients with non-proliferative diabetic retinopathy (NPDR). The follow-up time points will be 3 months, 6 months, 1 year, 2 years, and 3 years after enrollment or reaching the endpoint (any condition that needs retinal photocoagulation, anti-vascular endothelial growth factor injections, and pars plana vitrectomy). The study will collect both patient clinical characteristics and multi-model eye imaging. With use of an innovative AI model and a validated machine learning algorithm, based on multimodal vascular and neuro imaging of the eye, the progression of diabetic microangiopathy especially the DR could successfully be predictse and fundamentally facilitate diabetes management.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: At Enrollment
The progression of DR is based on the increase of DRSS score and classification.
Ophthalmologists at the Department of Ophthalmology, Peking University Third Hospital, will independently read UWF CFP in a semi-quantitative manner to assess the severity of DR based on the DRSS.
Progression of DR in T2DM patients with varying degrees of NPDR is calculated based on DRSS. An increase of at least one level in grading is considered progression. For instance, progression from grade 43A to 47A or higher is considered progression, while progression from 43A to 43B is not.
Time frame: At Enrollment
Progression to DN is considered when the UACR increases from < 30 mg/g to ≥ 30 mg/g.
Time frame: At Enrollment
Progression to DPN is considered when the MNSI score questionnaire section ≥ 4 points, while the examination section ≥ 2 points.
Contact information is provided by the study sponsor or research team.
Peking University Third Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07705607
Cardiovascular Diseases, Diabetes Complications
View Trial DetailsNCT07705555
Cardiovascular Diseases, Diabetes Complications
View Trial DetailsNCT07611682
Cardiovascular Diseases, Cataract
Rawalpindi, Punjab Province, Pakistan
View Trial DetailsNCT06763952
Cardiovascular Diseases, Diabetes Complications
Madison, Wisconsin, United States
View Trial Details